PMID-sentid	Pub_year	Sent_text		comp_official_name	comp_offsetprotein_name	organism	prot_offset
27438145-0	2016	Prexasertib, a Chk1/Chk2 inhibitor, increases the effectiveness of conventional therapy in B-/T- cell progenitor acute lymphoblastic leukemia.	prexasertib	0-11	checkpoint kinase 2	Homo sapiens	20-24	
33881209-1	2021	BACKGROUND: Prexasertib (LY2606368) is a novel, second-generation, selective dual inhibitor of checkpoint kinase proteins 1 (CHK1) and 2 (CHK2).	prexasertib	12-23	checkpoint kinase 2	Homo sapiens	138-142	
31512029-6	2020	Prexasertib (LY2606368) is a small ATP-competitive selective inhibitor of CHK1 and CHK2.	prexasertib	0-11	checkpoint kinase 2	Homo sapiens	83-87	
31512029-6	2020	Prexasertib (LY2606368) is a small ATP-competitive selective inhibitor of CHK1 and CHK2.	prexasertib	13-22	checkpoint kinase 2	Homo sapiens	83-87